World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
138
Citations
75784
World Ranking
1825
National Ranking
1042

Robert J. Mayer publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Robert J. Mayer sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 473 publications — 53rd percentile

53% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Robert J. Mayer D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Robert J. Mayer sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 138 D-Index — 91st percentile

91% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Robert J. Mayer is affiliated with the Dana-Farber Cancer Institute in the United States, contributing to research in both medicine and chemistry. Their scholarly output includes publications across several intersecting fields, centering predominantly on oncology and organic chemistry.

The main fields of study in their work include:

  • Medicine
  • Chemistry

Within these broader areas, Mayer's research touches on multiple subfields such as:

  • Organic Chemistry
  • Oncology
  • Materials Chemistry
  • Molecular Biology
  • Pathology and Forensic Medicine

Their primary research topics cover a range of specialized subjects, notably:

  • Colorectal Cancer Treatments and Studies
  • Crystallization and Solubility Studies
  • X-ray Diffraction in Crystallography
  • Genetic Factors in Colorectal Cancer
  • Gastric Cancer Management and Outcomes
  • Asymmetric Synthesis and Catalysis
  • Colorectal Cancer Screening and Detection

Mayer has authored multiple peer-reviewed papers, including the following representative works:

  • NCCN Guidelines Insights: Colorectal Cancer Screening, Version 2.2020, published in 2020 in the Journal of the National Comprehensive Cancer Network
  • Lewis Acidity Scale of Diaryliodonium Ions toward Oxygen, Nitrogen, and Halogen Lewis Bases, published in 2020 in the Journal of the American Chemical Society
  • From Carbodiimides to Carbon Dioxide: Quantification of the Electrophilic Reactivities of Heteroallenes, published in 2020 in the Journal of the American Chemical Society
  • Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial, published in 2020 in UNC Libraries
  • Lewis Acidic Boranes, Lewis Bases, and Equilibrium Constants: A Reliable Scaffold for a Quantitative Lewis Acidity/Basicity Scale, published in 2020 in Chemistry - A European Journal

The list of frequent coauthors who have collaborated with Mayer multiple times includes:

  • Armin R. Ofial
  • Donna Niedzwiecki
  • Richard M. Goldberg
  • Alan P. Venook
  • Jeffrey A. Meyerhardt

Publication venues where Mayer's work frequently appears include:

  • The Cambridge Structural Database
  • Journal of Clinical Oncology
  • UNC Libraries
  • Angewandte Chemie
  • Angewandte Chemie International Edition

Best Publications

  • Colorectal cancer screening: Clinical guidelines and rationale

    SJ Winawer;RH Fletcher;L Miller;F Godlee

  • Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

    John C. Byrd;Krzysztof Mrózek;Richard K. Dodge;Andrew J. Carroll

  • Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor

    Leonard B. Saltz;Neal J. Meropol;Patrick J. Loehrer;Michael N. Needle

  • Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

    Mayer Rj;Davis Rb;Schiffer Ca;Berg Dt

  • Systemic Therapy for Colorectal Cancer

    Jeffrey A. Meyerhardt;Robert J. Mayer

  • Phase III Trial of Trimodality Therapy With Cisplatin, Fluorouracil, Radiotherapy, and Surgery Compared With Surgery Alone for Esophageal Cancer: CALGB 9781

    Joel Tepper;Mark J. Krasna;Donna Niedzwiecki;Donna Hollis

  • Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer

    Robert J Mayer;Eric Van Cutsem;Alfredo Falcone;Takayuki Yoshino

  • Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery

    Michael J. O'Connell;James A. Martenson;Harry S. Wieand;James E. Krook

  • Colon Cancer Survival Is Associated With Increasing Number of Lymph Nodes Analyzed: A Secondary Survey of Intergroup Trial INT-0089

    T.E. Le Voyer;E.R. Sigurdson;A.L. Hanlon;R.J. Mayer

  • National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000.

    Eifel P;Axelson Ja;Costa J;Crowley J

  • Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)

    Hedy Lee Kindler;Donna Niedzwiecki;Donna Hollis;Susan Sutherland

  • Fluorouracil, Mitomycin, and Radiotherapy vs Fluorouracil, Cisplatin, and Radiotherapy for Carcinoma of the Anal Canal: A Randomized Controlled Trial

    Jaffer A. Ajani;Kathryn A. Winter;Leonard L. Gunderson;John Pedersen

  • Frequency of Prolonged Remission Duration after High-Dose Cytarabine Intensification in Acute Myeloid Leukemia Varies by Cytogenetic Subtype

    Clara D. Bloomfield;David Lawrence;John C. Byrd;Andrew Carroll

  • Impact of Physical Activity on Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803

    Jeffrey A. Meyerhardt;Denise Heseltine;Donna Niedzwiecki;Donna Hollis

  • Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial

    Alan P. Venook;Donna Niedzwiecki;Heinz Josef Lenz;Federico Innocenti

  • Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer.

    M J O'Connell;J A Mailliard;M J Kahn;J S Macdonald

  • Impact of Number of Nodes Retrieved on Outcome in Patients With Rectal Cancer

    Joel E. Tepper;Michael J. O’Connell;Donna Niedzwiecki;Donna Hollis

  • The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group.

    N Petrelli;H O Douglass;L Herrera;D Russell

  • Survival after postoperative combination treatment of rectal cancer.

    Douglass Ho;Moertel Cg;Mayer Rj;Thomas Pr

  • Chemoprevention of colorectal cancer.

    Pasi A. Jänne;Robert J. Mayer

Frequent Co-Authors

Donna Niedzwiecki
Donna Niedzwiecki Duke University
Jeffrey A. Meyerhardt
Jeffrey A. Meyerhardt Harvard University
Alan P. Venook
Alan P. Venook University of California, San Francisco
Monica M. Bertagnolli
Monica M. Bertagnolli Brigham and Women's Hospital
Al B. Benson
Al B. Benson Northwestern University
Richard M. Goldberg
Richard M. Goldberg West Virginia University
Leonard Saltz
Leonard Saltz Memorial Sloan Kettering Cancer Center
Howard S. Hochster
Howard S. Hochster Yale University
Heinz-Josef Lenz
Heinz-Josef Lenz University of Southern California

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're considering a career in Medicine but want to explore flexible or alternative pathways, online degrees can open exciting doors. Many choose nursing as an entry point, often starting out with the fastest LPN program to quickly qualify for healthcare positions and gain hands-on experience.

For those interested in advanced practice and mental health, the fastest psychiatric nurse practitioner program offers a quick path to specialized roles, helping you make a difference in psychiatric care.

Beyond clinical work, many students shift their focus to healthcare management. With a health care administration degree online, you can prepare for leadership roles, often while balancing work and study.

Considering cost is important, especially for master’s programs. Be sure to compare options and understand the cost of MHA degree programs to ensure your investment aligns with your career goals.

Best Scientists Citing Robert J. Mayer

Trending Scientists